Enliven Therapeutics ELVN Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's interest expense?
- Enliven Therapeutics (ELVN) reported interest expense of $4.2M in Q1 2026.
- How has Enliven Therapeutics's interest expense changed year-over-year?
- Enliven Therapeutics's interest expense increased by 31.3% year-over-year, from $3.2M to $4.2M.
- What is the long-term trend for Enliven Therapeutics's interest expense?
- Over 4 years (2021 to 2025), Enliven Therapeutics's interest expense has grown at a 187.9% compound annual growth rate (CAGR), from $233K to $16.01M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.